Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A.

Kelaidi C, Braun T, Arana R, Marceau-Renaut A, Lazarian G, Soret J, Cereja S, Letestu R, Eclache V, Lusina D, Baran-Marszak F, Ades L, Preudhomme C, Martin A, Fenaux P, Gardin C.

Leuk Res. 2018 Aug;71:67-74. doi: 10.1016/j.leukres.2018.05.007. Epub 2018 May 29.

PMID:
30025278
2.

Induction of endoplasmic reticulum calcium pump expression during early leukemic B cell differentiation.

Aït Ghezali L, Arbabian A, Roudot H, Brouland JP, Baran-Marszak F, Salvaris E, Boyd A, Drexler HG, Enyedi A, Letestu R, Varin-Blank N, Papp B.

J Exp Clin Cancer Res. 2017 Jun 26;36(1):87. doi: 10.1186/s13046-017-0556-7.

3.

Obstructive sleep apnoea and related comorbidities in incident idiopathic pulmonary fibrosis.

Gille T, Didier M, Boubaya M, Moya L, Sutton A, Carton Z, Baran-Marszak F, Sadoun-Danino D, Israël-Biet D, Cottin V, Gagnadoux F, Crestani B, d'Ortho MP, Brillet PY, Valeyre D, Nunes H, Planès C; collaborators.

Eur Respir J. 2017 Jun 8;49(6). pii: 1601934. doi: 10.1183/13993003.01934-2016. Print 2017 Jun.

4.

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.

Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi T.

Cancer Res. 2017 Mar 15;77(6):1250-1260. doi: 10.1158/0008-5472.CAN-16-2179. Review.

5.

TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes.

Lazarian G, Tausch E, Eclache V, Sebaa A, Bianchi V, Letestu R, Collon JF, Lefebvre V, Gardano L, Varin-Blank N, Soussi T, Stilgenbauer S, Cymbalista F, Baran-Marszak F.

Int J Cancer. 2016 Oct 15;139(8):1759-63. doi: 10.1002/ijc.30222. Epub 2016 Jun 24.

6.

Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.

Bernard S, Danglade D, Gardano L, Laguillier C, Lazarian G, Roger C, Thieblemont C, Marzec J, Gribben J, Cymbalista F, Varin-Blank N, Ledoux D, Baran-Marszak F.

Int J Cancer. 2015 Jun 15;136(12):2761-74. doi: 10.1002/ijc.29326. Epub 2014 Dec 3.

7.

Old DAT and new data: positive direct antiglobulin test identifies a subgroup with poor outcome among chronic lymphocytic leukemia stage A patients.

Quinquenel A, Al Nawakil C, Baran-Marszak F, Eclache V, Letestu R, Khalloufi M, Boubaya M, Le Roy C, Varin-Blank N, Delmer A, Levy V, Ajchenbaum-Cymbalista F.

Am J Hematol. 2015 Jan;90(1):E5-8. doi: 10.1002/ajh.23861. Epub 2014 Oct 25.

8.

Association of a single-nucleotide polymorphism in the SH2B3 gene with JAK2V617F-positive myeloproliferative neoplasms.

Lesteven E, Picque M, Conejero Tonetti C, Giraudier S, Varin-Blank N, Velazquez L, Kiladjian JJ, Cassinat B, Baran-Marszak F.

Blood. 2014 Jan 30;123(5):794-6. doi: 10.1182/blood-2013-10-532622. No abstract available.

9.

STAT3 inhibitors for cancer therapy: Have all roads been explored?

Fagard R, Metelev V, Souissi I, Baran-Marszak F.

JAKSTAT. 2013 Jan 1;2(1):e22882. doi: 10.4161/jkst.22882. Review.

10.

Targeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma.

Boukhiar MA, Roger C, Tran J, Gressin R, Martin A, Ajchenbaum-Cymbalista F, Varin-Blank N, Ledoux D, Baran-Marszak F.

Exp Hematol Oncol. 2013 Feb 19;2(1):4. doi: 10.1186/2162-3619-2-4.

11.

A STAT3-inhibitory hairpin decoy oligodeoxynucleotide discriminates between STAT1 and STAT3 and induces death in a human colon carcinoma cell line.

Souissi I, Ladam P, Cognet JA, Le Coquil S, Varin-Blank N, Baran-Marszak F, Metelev V, Fagard R.

Mol Cancer. 2012 Mar 16;11:12. doi: 10.1186/1476-4598-11-12.

12.

Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia.

Thépot S, Lainey E, Cluzeau T, Sébert M, Leroy C, Adès L, Tailler M, Galluzzi L, Baran-Marszak F, Roudot H, Eclache V, Gardin C, de Botton S, Auberger P, Fenaux P, Kroemer G, Boehrer S.

Cell Cycle. 2011 Jul 15;10(14):2323-30. Epub 2011 Jul 15.

PMID:
21654193
13.

A STAT3-decoy oligonucleotide induces cell death in a human colorectal carcinoma cell line by blocking nuclear transfer of STAT3 and STAT3-bound NF-κB.

Souissi I, Najjar I, Ah-Koon L, Schischmanoff PO, Lesage D, Le Coquil S, Roger C, Dusanter-Fourt I, Varin-Blank N, Cao A, Metelev V, Baran-Marszak F, Fagard R.

BMC Cell Biol. 2011 Apr 12;12:14. doi: 10.1186/1471-2121-12-14.

14.

Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms.

Baran-Marszak F, Magdoud H, Desterke C, Alvarado A, Roger C, Harel S, Mazoyer E, Cassinat B, Chevret S, Tonetti C, Giraudier S, Fenaux P, Cymbalista F, Varin-Blank N, Le Bousse-Kerdilès MC, Kiladjian JJ, Velazquez L.

Blood. 2010 Dec 23;116(26):5961-71. doi: 10.1182/blood-2009-12-256768. Epub 2010 Sep 24.

15.

Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters.

Letestu R, Lévy V, Eclache V, Baran-Marszak F, Vaur D, Naguib D, Schischmanoff O, Katsahian S, Nguyen-Khac F, Davi F, Merle-Béral H, Troussard X, Ajchenbaum-Cymbalista F.

Blood. 2010 Nov 25;116(22):4588-90. doi: 10.1182/blood-2010-06-288274. Epub 2010 Aug 25.

16.

Routine diagnostic procedures of myelodysplastic syndromes: value of a structural blood cell parameter (NEUT-X) determined by the Sysmex XE-2100™.

Le Roux G, Vlad A, Eclache V, Malanquin C, Collon JF, Gantier M, Schillinger F, Peltier JY, Savin B, Letestu R, Baran-Marszak F, Fenaux P, Ajchenbaum-Cymbalista F.

Int J Lab Hematol. 2010 Dec;32(6 Pt 1):e237-43. doi: 10.1111/j.1751-553X.2010.01247.x.

PMID:
20670338
17.

Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma.

Baran-Marszak F, Boukhiar M, Harel S, Laguillier C, Roger C, Gressin R, Martin A, Fagard R, Varin-Blank N, Ajchenbaum-Cymbalista F, Ledoux D.

Haematologica. 2010 Nov;95(11):1865-72. doi: 10.3324/haematol.2009.019745. Epub 2010 Jul 27.

18.

Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B-cell receptor ligation and associated with progressive disease.

Vlad A, Deglesne PA, Letestu R, Saint-Georges S, Chevallier N, Baran-Marszak F, Varin-Blank N, Ajchenbaum-Cymbalista F, Ledoux D.

Cancer Res. 2009 Aug 15;69(16):6387-95. doi: 10.1158/0008-5472.CAN-08-4750. Epub 2009 Aug 4.

19.

Efficient killing of SW480 colon carcinoma cells by a signal transducer and activator of transcription (STAT) 3 hairpin decoy oligodeoxynucleotide--interference with interferon-gamma-STAT1-mediated killing.

Tadlaoui Hbibi A, Laguillier C, Souissi I, Lesage D, Le Coquil S, Cao A, Metelev V, Baran-Marszak F, Fagard R.

FEBS J. 2009 May;276(9):2505-15. doi: 10.1111/j.1742-4658.2009.06975.x. Epub 2009 Mar 16.

20.

Novel function of STAT1beta in B cells: induction of cell death by a mechanism different from that of STAT1alpha.

Najjar I, Schischmanoff PO, Baran-Marszak F, Deglesne PA, Youlyouz-Marfak I, Pampin M, Feuillard J, Bornkamm GW, Chelbi-Alix MK, Fagard R.

J Leukoc Biol. 2008 Dec;84(6):1604-12. doi: 10.1189/jlb.0508287. Epub 2008 Sep 11.

PMID:
18753311
21.

Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents.

Youlyouz-Marfak I, Gachard N, Le Clorennec C, Najjar I, Baran-Marszak F, Reminieras L, May E, Bornkamm GW, Fagard R, Feuillard J.

Cell Death Differ. 2008 Feb;15(2):376-85. Epub 2007 Nov 9.

22.

Cell death in NF-kappaB-dependent tumour cell lines as a result of NF-kappaB trapping by linker-modified hairpin decoy oligonucleotide.

Laguillier C, Hbibi AT, Baran-Marszak F, Metelev V, Cao A, Cymbalista F, Bogdanov A Jr, Fagard R.

FEBS Lett. 2007 Mar 20;581(6):1143-50. Epub 2007 Feb 20.

23.

C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma.

Schlee M, Hölzel M, Bernard S, Mailhammer R, Schuhmacher M, Reschke J, Eick D, Marinkovic D, Wirth T, Rosenwald A, Staudt LM, Eilers M, Baran-Marszak F, Fagard R, Feuillard J, Laux G, Bornkamm GW.

Int J Cancer. 2007 Apr 1;120(7):1387-95.

24.

Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of Zap70 expression.

Deglesne PA, Chevallier N, Letestu R, Baran-Marszak F, Beitar T, Salanoubat C, Sanhes L, Nataf J, Roger C, Varin-Blank N, Ajchenbaum-Cymbalista F.

Cancer Res. 2006 Jul 15;66(14):7158-66.

25.

Effect of tumor necrosis factor alpha and infliximab on apoptosis of B lymphocytes infected or not with Epstein-Barr virus.

Baran-Marszak F, Laguillier C, Youlyouz I, Feuillard J, Mariette X, Fagard R, Raphaël M.

Cytokine. 2006 Mar 21;33(6):337-45. Epub 2006 May 19.

PMID:
16713282
26.
27.

Increasing level of CD56+ T-cells in peripheral blood in sarcoidosis.

Naccache JM, Kambouchner M, Schischmanoff PO, Baran-Marszak F, Raphaël M, Fagard R, Valeyre D.

Eur Respir J. 2006 Mar;27(3):654. No abstract available.

28.

Latent membrane protein 1 regulates STAT1 through NF-kappaB-dependent interferon secretion in Epstein-Barr virus-immortalized B cells.

Najjar I, Baran-Marszak F, Le Clorennec C, Laguillier C, Schischmanoff O, Youlyouz-Marfak I, Schlee M, Bornkamm GW, Raphaël M, Feuillard J, Fagard R.

J Virol. 2005 Apr;79(8):4936-43.

29.

HIV+ MALT lymphoma remission induced by highly active antiretroviral therapy alone.

Girard T, Luquet-Besson I, Baran-Marszak F, Raphaël M, Boué F.

Eur J Haematol. 2005 Jan;74(1):70-2.

PMID:
15613110
30.

Differential roles of STAT1alpha and STAT1beta in fludarabine-induced cell cycle arrest and apoptosis in human B cells.

Baran-Marszak F, Feuillard J, Najjar I, Le Clorennec C, Béchet JM, Dusanter-Fourt I, Bornkamm GW, Raphaël M, Fagard R.

Blood. 2004 Oct 15;104(8):2475-83. Epub 2004 Jun 24.

31.

The chemopreventive agent N-(4-hydroxyphenyl)retinamide induces apoptosis through a mitochondrial pathway regulated by proteins from the Bcl-2 family.

Boya P, Morales MC, Gonzalez-Polo RA, Andreau K, Gourdier I, Perfettini JL, Larochette N, Deniaud A, Baran-Marszak F, Fagard R, Feuillard J, Asumendi A, Raphael M, Pau B, Brenner C, Kroemer G.

Oncogene. 2003 Sep 18;22(40):6220-30.

PMID:
13679861
32.

Specific covalent binding of a NF-kappaB decoy hairpin oligonucleotide targeted to the p50 subunit and induction of apoptosis.

Lesage D, Metelev V, Borisova O, Dolinnaya N, Oretskaya T, Baran-Marszak F, Taillandier E, Raphael M, Fagard R.

FEBS Lett. 2003 Jul 17;547(1-3):115-8.

33.

Gene array identification of Epstein Barr virus-regulated cellular genes in EBV-converted Burkitt lymphoma cell lines.

Baran-Marszak F, Fagard R, Girard B, Camilleri-Broët S, Zeng F, Lenoir GM, Raphaël M, Feuillard J.

Lab Invest. 2002 Nov;82(11):1463-79.

PMID:
12429807

Supplemental Content

Loading ...
Support Center